Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPEAL: Almonertinib +/- Chemo in EGFR T790M+ NSCLC
NCT04592666Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Oct 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04592666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04592666.